Management of early breast cancer has become increasingly successful, leading to current 10-year survival rates of around
80-85%. Approximately 75% of breast cancers are hormone-receptor-positive, and these patients are usually managed in the adjuvant
setting with targeted hormonal agents, and if indicated, cytotoxic chemotherapy. These treatments are not without side effects,
and of particular ... [Show full abstract] relevance to the older woman is their impact on skeletal health.